Earnings

Neuphoria Therapeutics Q4 EPS $(0.95) Misses $(0.56) Estimate, Sales $1.174M.

Sep 18, 2026 · 05:26 PM ET· updated 2h ago

Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.56) by 69.64 percent. This is a 76.13 percent increase over losses of $(3.98) per

Why It Matters

Neuphoria lost more money per share than expected this quarter. When a company loses more than people thought, watch if they explain why clearly.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NEUP3.74

+0.03 (+0.67%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.